Table 4.

Comparison of grade ≥ 3 adverse events between the experimental group and the control group.

Grade ≥ 3 adverse events	Number of studies	Heterogeneity	OR 95%CI	P
Elevated ALT	2	P = .32, I2 = 0%	14.43 (3.95–52.80)	<.0001
Elevated AST	2	P = .49, I2 = 0%	14.46 (4.78–43.75)	<.00001
Hyperbilirubinemia	2	P = .14, I2 = 53%	1.96 (0.59–6.45)	.27
Hypertension	8	P = .15, I2 = 35%	1.55 (1.08–2.23)	.02
Fatigue	6	P = .58, I2 = 0%	1.00 (0.46–2.15)	.99
Diarrhea	7	P = .96, I2 = 0%	1.41 (0.70–2.84)	.33
Abdominal pain	3	P = .27, I2 = 25%	2.26 (0.77–6.66)	.14
Hand-foot skin reaction	6	P = .59, I2 = 0%	1.72 (0.58–5.09)	.33
Leukopenia or thrombocytopenia	4	P = .98, I2 = 0%	1.28 (0.55–2.97)	.57
Decreased appetite	5	P = .64, I2 = 0%	0.86 (0.41–1.80)	.70
Albuminuria	5	P = .68, I2 = 0%	0.88 (0.44–1.76)	.71
Hoarseness	5	P = .85, I2 = 0%	0.42 (0.06–2.88)	.38
Fever	4	P = .98, I2 = 0%	3.59 (0.74–17.51)	.11
Weight decrease	3	P = .72, I2 = 0%	0.99 (0.50–1.95)	.98
Rash	2	P = .82, I2 = 0%	2.21 (0.49–9.95)	.30
Nausea and vomiting	2	P = .71, I2 = 0%	0.87 (0.31–2.45)	.79
Constipation	3	P = .80, I2 = 0%	0.74 (0.16–3.34)	.70

ALT = alanine aminotransferase, AST = aspartate aminotransferase, CI = confidence interval, OR = odds ratio.